Which substances are discussed?
The policy addresses specified forms of BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax. The conditions differ by substance and route. A name on this list is not a general authorization to make every version or combination.
What conditions must be checked?
The HHS document describes qualifying 503A compounders, a patient-specific prescription, specified ingredient and route, ingredient sourcing and testing, labeling, reporting, and a single listed active ingredient per product. For some forms, additional conditions apply. A clinician and dispensing pharmacy must assess the current policy and the individual situation.
The single-ingredient condition is particularly relevant to searches for BPC-157/TB-500 or Semax/Selank blends. This interim policy does not cover a multi-ingredient product simply because one ingredient appears on its list.
Does this mean FDA approved the peptides?
No. Compounded drugs are not FDA approved and have not undergone FDA review for safety, effectiveness, or quality before marketing. FDA separately describes safety concerns and evidence gaps for several of these bulk substances. Enforcement discretion is a limited regulatory position that can be changed; it is not a clinical endorsement.
What should a patient verify?
- What condition is being evaluated and which established treatments are appropriate?
- Is the proposed substance and formulation within the current policy's exact scope?
- Who compounds and dispenses it, and what ingredient identity and lot testing are available?
- What risks, uncertainty, follow-up, and adverse-event reporting should be discussed?
- Is any specific product actually available and appropriate in the patient's state?
A clinical assessment can help frame these questions. It does not guarantee a prescription or product availability.
Primary sources
This page is informational and not medical or legal advice. Treatment through Jonathan Larson MDPC requires a licensed clinician's evaluation.